PPD Key Statistics, Chart & Performance
The current stock price of PPD is 47.28 null. In the past month the price increased by 0.06%. In the past year, price increased by 37.36%.
PPD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 27.08 | 227.87B | ||
| DHR | DANAHER CORP | 30.48 | 165.99B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 200.24 | 60.85B | ||
| A | AGILENT TECHNOLOGIES INC | 26.12 | 41.32B | ||
| IQV | IQVIA HOLDINGS INC | 20.91 | 41.42B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 35.02 | 29.93B | ||
| WAT | WATERS CORP | 31.23 | 23.61B | ||
| ILMN | ILLUMINA INC | 33.45 | 22.28B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 38.93 | 19.80B | ||
| MEDP | MEDPACE HOLDINGS INC | 41.96 | 16.90B | ||
| TEM | TEMPUS AI INC | N/A | 12.16B | ||
| RVTY | REVVITY INC | 21.23 | 11.53B |
Related stock screener links
About PPD
Company Profile
PPD, Inc. engages in the provision of drug development services to the biopharmaceutical industry, focuses on helping customers bring their new medicines to patients around the world. The company is headquartered in Wilmington, North Carolina and currently employs 26,000 full-time employees. The company went IPO on 2020-02-06. The firm provides clinical development and laboratory services to pharmaceutical, biotechnology, medical device and government organizations, as well as other industry participants. The firm operates through two segments: Clinical Development Services and Laboratory Services. The Clinical Development Services segment provides a range of services to its customers including early development/Phase I, patient recruitment and enrollment, investigator site management, Phase II-IV clinical trial management, medical communications and various peri- and post-approval services. The Laboratory Services segment provides services to its customers including bioanalytical, vaccine sciences, good manufacturing practice (GMP), central lab and biomarker testing.
Company Info
PPD Inc
929 North Front Street
Wilmington NORTH CAROLINA 28401 US
CEO: David Simmons
Employees: 26000
Phone: 19102510081.0
PPD Inc / PPD FAQ
What does PPD Inc do?
PPD, Inc. engages in the provision of drug development services to the biopharmaceutical industry, focuses on helping customers bring their new medicines to patients around the world. The company is headquartered in Wilmington, North Carolina and currently employs 26,000 full-time employees. The company went IPO on 2020-02-06. The firm provides clinical development and laboratory services to pharmaceutical, biotechnology, medical device and government organizations, as well as other industry participants. The firm operates through two segments: Clinical Development Services and Laboratory Services. The Clinical Development Services segment provides a range of services to its customers including early development/Phase I, patient recruitment and enrollment, investigator site management, Phase II-IV clinical trial management, medical communications and various peri- and post-approval services. The Laboratory Services segment provides services to its customers including bioanalytical, vaccine sciences, good manufacturing practice (GMP), central lab and biomarker testing.
What is the current price of PPD stock?
The current stock price of PPD is 47.28 null. The price decreased by -0.06% in the last trading session.
What is the dividend status of PPD Inc?
PPD does not pay a dividend.
What is the ChartMill technical and fundamental rating of PPD stock?
PPD has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Can you provide the number of employees for PPD Inc?
PPD Inc (PPD) currently has 26000 employees.
Can you provide the market cap for PPD Inc?
PPD Inc (PPD) has a market capitalization of 17.00B null. This makes PPD a Large Cap stock.
PPD Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to PPD. When comparing the yearly performance of all stocks, PPD is one of the better performing stocks in the market, outperforming 82.3% of all stocks.
PPD Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to PPD. Both the profitability and the financial health of PPD get a neutral evaluation. Nothing too spectacular is happening here.
PPD Financial Highlights
Over the last trailing twelve months PPD reported a non-GAAP Earnings per Share(EPS) of 1.56. The EPS increased by 39.29% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 6.19% | ||
| ROA | 5.18% | ||
| ROE | N/A | ||
| Debt/Equity | -9.91 |
PPD Forecast & Estimates
17 analysts have analysed PPD and the average price target is 48.25 null. This implies a price increase of 2.04% is expected in the next year compared to the current price of 47.28.
For the next year, analysts expect an EPS growth of 37.26% and a revenue growth 31.13% for PPD